» Articles » PMID: 35628614

Bone Involvement in Systemic Lupus Erythematosus

Overview
Journal Int J Mol Sci
Publisher MDPI
Date 2022 May 28
PMID 35628614
Authors
Affiliations
Soon will be listed here.
Abstract

Systemic lupus erythematosus (SLE) is a chronic autoimmune disease characterized by a wide variability of clinical manifestations due to the potential involvement of several tissues and internal organs, with a relapsing and remitting course. Dysregulation of innate and adaptive immune systems, due to genetic, hormonal and environmental factors, may be responsible for a broad spectrum of clinical manifestations, affecting quality of life, morbidity and mortality. Bone involvement represents one of the most common cause of morbidity and disability in SLE. Particularly, an increased incidence of osteoporosis, avascular necrosis of bone and osteomyelitis has been observed in SLE patients compared to the general population. Moreover, due to the improvement in diagnosis and therapy, the survival of SLE patient has improved, increasing long-term morbidities, including osteoporosis and related fractures. This review aims to highlight bone manifestations in SLE patients, deepening underlying etiopathogenetic mechanisms, diagnostic tools and available treatment.

Citing Articles

Factors influencing therapeutic efficacy of denosumab against osteoporosis in systemic lupus erythematosus.

Yang J, Park Y, Lee J, Kwok S, Ju J, Kim W Lupus Sci Med. 2025; 12(1).

PMID: 39843360 PMC: 11759218. DOI: 10.1136/lupus-2024-001438.


The Relationship Between Systemic Lupus Erythematosus and Osteoporosis Based on Different Ethnic Groups: a Two-Sample Mendelian Randomization Analysis.

Shi Y, Yuan K, Fu Z, Hu R, Wang H Calcif Tissue Int. 2024; 114(4):386-396.

PMID: 38355832 DOI: 10.1007/s00223-024-01190-8.


Systemic lupus erythematosus Association between Osteomyelitis: A two-sample Mendelian randomization study in European population.

Hu M, Sun Z, Tang X, Zeng W, Yan H, Jiang Z Heliyon. 2023; 9(12):e22999.

PMID: 38125497 PMC: 10731233. DOI: 10.1016/j.heliyon.2023.e22999.


Inflammatory Processes Affecting Bone Health and Repair.

Torres H, Arnold K, Oviedo M, Westendorf J, Weaver S Curr Osteoporos Rep. 2023; 21(6):842-853.

PMID: 37759135 PMC: 10842967. DOI: 10.1007/s11914-023-00824-4.

References
1.
Kim C, Han K, Jung J, Choi H, Bae E, Ma S . Incidence and risk factors for osteoporotic fractures in patients with systemic lupus erythematosus versus matched controls. Korean J Intern Med. 2019; 36(1):154-163. PMC: 7820659. DOI: 10.3904/kjim.2018.378. View

2.
Fava A, Petri M . Systemic lupus erythematosus: Diagnosis and clinical management. J Autoimmun. 2018; 96:1-13. PMC: 6310637. DOI: 10.1016/j.jaut.2018.11.001. View

3.
Mont M, Pivec R, Banerjee S, Issa K, Elmallah R, Jones L . High-Dose Corticosteroid Use and Risk of Hip Osteonecrosis: Meta-Analysis and Systematic Literature Review. J Arthroplasty. 2015; 30(9):1506-1512.e5. PMC: 7127809. DOI: 10.1016/j.arth.2015.03.036. View

4.
Herrinton L, Liu L, Goldfien R, Michaels M, Tran T . Risk of Serious Infection for Patients with Systemic Lupus Erythematosus Starting Glucocorticoids with or without Antimalarials. J Rheumatol. 2016; 43(8):1503-9. DOI: 10.3899/jrheum.150671. View

5.
Canella C, Costa F, Danowisk A, de Melo A, Marchiori E . Stress fracture and osteomyelitis in a patient with systemic lupus erythematosus. Radiol Bras. 2018; 51(4):277-278. PMC: 6124598. DOI: 10.1590/0100-3984.2017.0035. View